Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Benchmark reiterated a “buy” rating and set a $5.00 price objective on shares of Clene in a research report on Thursday, May 23rd.

Clene Trading Up 1.7 %

NASDAQ:CLNN opened at $0.38 on Tuesday. The stock has a fifty day simple moving average of $0.37 and a 200 day simple moving average of $0.40. The firm has a market capitalization of $48.82 million, a price-to-earnings ratio of -0.83 and a beta of 0.45. Clene has a 1-year low of $0.25 and a 1-year high of $1.02. The company has a quick ratio of 1.22, a current ratio of 1.23 and a debt-to-equity ratio of 1.66.

Clene (NASDAQ:CLNN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Clene had a negative net margin of 7,873.23% and a negative return on equity of 224.28%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts forecast that Clene will post -0.34 earnings per share for the current year.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.